|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3091 USD | -3.86% |
|
-15.18% | -56.59% |
Company Valuation: Scinai Immunotherapeutics Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 32.39 | 43.42 | 10.32 | 2.591 | 2.853 | 2.47 |
| Change | - | 34.05% | -76.24% | -74.89% | 10.12% | -13.44% |
| Enterprise Value (EV) 1 | 90.13 | 59.12 | 17.78 | 18.28 | 2.975 | 3.076 |
| Change | - | -34.41% | -69.92% | 2.8% | -83.73% | 3.38% |
| P/E | -6.99x | -0.83x | -0.74x | -0.36x | - | -0.2x |
| PBR | -2.22x | 1.9x | -5.52x | -0.61x | 0.66x | 1x |
| PEG | - | -0x | 0x | 0x | - | - |
| Capitalization / Revenue | - | - | - | - | 4,336,274x | 1,883,846x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | 10.2x | -1.77x | -1.69x | -1.99x | -0.43x | -0.5x |
| EV / EBIT | 12.3x | -1.7x | -1.61x | -1.88x | -0.34x | -0.41x |
| EV / FCF | -14.9x | -4.18x | -2.07x | -3.1x | -0.78x | -0.92x |
| FCF Yield | -6.7% | -23.9% | -48.2% | -32.3% | -128% | -108% |
| Dividend per Share 3 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 3 | -40.2 | -283.2 | -40 | -16.64 | - | -3.558 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | 0.658 | 1.311 |
| EBITDA 1 | 8.84 | -33.31 | -10.5 | -9.192 | -6.989 | -6.121 |
| EBIT 1 | 7.334 | -34.83 | -11.06 | -9.706 | -8.638 | -7.542 |
| Net income 1 | -4.455 | -39.98 | -5.796 | -6.5 | 4.796 | -8.307 |
| Net Debt 1 | 57.74 | 15.7 | 7.467 | 15.69 | 0.122 | 0.606 |
| Reference price 3 | 281.0000 | 235.0000 | 29.6000 | 5.9540 | 3.3450 | 0.7121 |
| Nbr of stocks (in thousands) | 115 | 185 | 349 | 435 | 853 | 3,468 |
| Announcement Date | 5/13/21 | 3/28/22 | 4/17/23 | 5/15/24 | 5/7/25 | 4/1/26 |
1USD in Million2ILS in Million3USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.27M | |
| 30.11x | 5.34x | 16.53x | 1.09% | 43.13B | |
| -20.5x | 304.3x | -18.74x | -.--% | 34.65B | |
| 40.3x | 4.01x | 25.68x | -.--% | 30.03B | |
| 20.41x | 2.41x | 10.42x | -.--% | 28B | |
| 28.67x | 7.42x | 19.09x | 0.44% | 24.45B | |
| 27x | 4.32x | 19.66x | -.--% | 13.14B | |
| 21.71x | 1.89x | 8.32x | 1.23% | 12.53B | |
| -20.52x | 13.52x | -20.12x | -.--% | 12.25B | |
| Average | 15.90x | 42.90x | 7.61x | 0.34% | 22.02B | |
| Weighted average by Cap. | 17.39x | 57.47x | 8.63x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SCNI Stock
- Valuation Scinai Immunotherapeutics Ltd.
Select your edition
All financial news and data tailored to specific country editions
